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a b s t r a c t
Individuals carrying the *E4 allele of the apolipoprotein E gene (APOE) are at increased risk of develop-
ing Alzheimer’s disease (AD). However, the biological mechanisms underlying this association are still
unclear because of the complexity of the pathological processes that cause AD. Furthermore, the effect
of APOE genotype on development, maintenance and aging of the normal brain is poorly understood
because of the strong bias toward studying disease associations. In vivo techniques such as neuroimag-
ing and cognitive testing offer valuable insights into the effects of APOE genotype on brain structure
and function in healthy and clinical populations. We review the evidence from in vivo studies thatpoE
lzheimer’s disease
ild cognitive impairment
eurodegeneration
hite matter integrity
maging
APOE *E4, in addition to increasing the chance of age-related pathological events, is associated with
age-independent non-pathological changes in brain physiology, some of which make the brain less
resilient to neurodegenerative processes. We argue that the interaction between the APOE-dependent
non-pathological vulnerabilities and age-related pathological changes is onemechanism that can trigger
neurodegeneration, resulting in AD and other complex phenotypes.ognition © 2013 Published by Elsevier Ltd.
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. Introduction
In the context of generally weak associations of speciﬁc genes
ith complex traits or diseases, the strong association of the
polipoprotein E gene APOE with Alzheimer’s disease (AD) stands
ut as an exception (Genin et al., 2011). Individuals carrying the
POE *E4 allele are at increased risk of developing AD and have
ecreased age of onset (Corder et al., 1993; Raber et al., 2004;
trittmatter et al., 1993), but the biological mechanisms underly-
ng these observations are poorly understood. Given the growing
urden of AD-related morbidity (Sperling et al., 2011), the issue of
ow APOE genotype affects a broad range of biological processes
cross the lifespan is of considerable clinical and scientiﬁc interest.
ApoE is essential for normal lipid homeostasis in the brain
Bu, 2009; Holtzman et al., 2012) and there is growing evidence
hat APOE genotype inﬂuences multiple physiological pathways
Mahley et al., 2006). We review the evidence that APOE *E4 has
ffects on brain structure and function that are not in themselves
athological, but appear tomake the brainmore susceptible to age-
ssociated pathological mechanisms. The mechanisms reviewed
re important because they are relevant for risk evaluation and
ccessible to studies with in vivo imaging or behavioral methods.
evelopment of neurodegenerative pathology is dependent on a
umberof factors (Holtzmanet al., 2012), someofwhich are related
o APOE genotype and some not. The early stages of pathological
ognitive change (mild cognitive impairment –MCI) are extremely
eterogenous (Stephan et al., 2012) and there is a clear need to
dentify a speciﬁcAPOE-relatedpathophysiological phenotypewith
ehavioral and imaging markers.
We argue that the onset of neurodegenerative disease is caused
y interaction of APOE-related vulnerabilities with age-dependent
athological mechanisms. The most important of these is accu-
ulation of amyloid , but other factors such as accelerated rate
f degeneration of cholinergic neurons and APOE-related vascular
bnormalities may also signiﬁcantly inﬂuence the clinical pheno-
ype.
We aim to answer the following questions:
. How does APOE *E4 increase the risk of early presentation of
Alzheimer’s disease?
. Why do some carriers of *E4 not develop AD?
. When does APOE genotype ﬁrst affect the biomarker phenotype
and what are the underlying mechanisms?. Which biomarkers are most sensitive to ApoE-related mecha-
nisms?
. Are there clinical phenotypes speciﬁcally related to APOE geno-
type?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332
1.1. APOE and AD risk
APOE is a 3.6Kbgeneonchromosome19. It encodes a299-amino
acid protein with functionally signiﬁcant variations in codons 112
(Cys/Arg) and 158 (Cys/Arg) leading to 3 common isoforms: ApoE
2, Cys112/Cys158 (encoded by the APOE *E2 allele), ApoE 3,
Cys112/Arg158 (encoded by the APOE *E3 allele), and ApoE 4,
Arg112/Arg158 (encoded by the APOE *E4 allele). The *E4 allele
causes a dose-dependent increase in risk of developing AD (Corder
et al., 1993; Strittmatter et al., 1993) and decreases the age of diag-
nosis (Raber et al., 2004). *E4 homozygosity confers about 14 times
increase in lifetime risk compared to *E3 homozygosity, but in an
age-dependent manner, with a maximum relative risk of 35 in the
age group 60–69 (Genin et al., 2011). *E3/*E4 heterozygotes have
a 4-fold increase in relative risk compared to *E3 homozygotes for
all ages above 60. The frequency of the *E4 allele varies in different
populations (Gerdes, 2003), and in some ethnic groups *E4 has a
weaker or no clear effect on AD risk (Kalaria et al., 2008; Mayeux,
2003). TheAPOE *E4 allele is the strongest knowngenetic risk factor
for AD, yet the basis of this association is poorly understood owing
to the complexity of the underlying pathophysiological mecha-
nisms. AD, the most common form of age-related dementia, is
characterized by neuronal degeneration, synaptic loss, brain atro-
phy and accumulation of insoluble aggregates of amyloid and tau
proteins (Verghese et al., 2011). The ApoE protein has been impli-
cated in many of the processes that are thought to cause these
devastating changes (Holtzman et al., 2012; Mahley et al., 2006;
Verghese et al., 2011), but it has proven very difﬁcult to identify
the speciﬁc effects of APOE genotype that are most important for
the initiation andprogressionof pathologicalmechanisms. Another
major challenge is to determine whether APOE genotype affects
the structure and function of the normal brain, through roles in
neurodevelopment, maintenance and repair.
1.2. Physiological functions of ApoE in the brain
ApoE is strongly expressed in brain and liver and transports
lipids, including cholesterol, through the cerebrospinal ﬂuid (CSF)
and plasma (Bu, 2009; Holtzman et al., 2012). In the brain, ApoE is
synthesized by astrocytes and microglia but can also be produced
by neurons following injury. Cholesterol, an essential component
of cell membranes and myelin, is required for development, main-
tenance and repair of myelin sheaths, neuronal membranes and
synaptic connections (Pfrieger, 2003). ApoE plays a signiﬁcant role
in supplying cholesterol for these processes. Several pathogenic
factors leading to cell damage, including ischemia, put increasing
stress on repair mechanisms and lead to upregulation of ApoE
(Bu, 2009). The surge in ApoE levels after neuronal injury may
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e important for synaptic and membrane repair by redistributing
ipids and cholesterol (Holtzman et al., 2012). There is no in vivo
iomarker uniquely associated with synaptogenesis or synaptic
ensity, but several magnetic resonance imaging (MRI) parame-
ers, both morphometric and microstructural, may be indirectly
ffected (see Table 1).
.3. Methods for studying the effects of APOE genotype on brain
tructure and function
The effects of APOE genotype on the brain in healthy and clinical
opulations can be studied using in vivo techniques such as imag-
ng and behavioral studies. A selective summary of some of these
ethods is provided in Table 1.
. Non-pathological effects of APOE genotype on the
ormal aging brain
.1. Myelination.1.1. Myelination in aging
Developmentalmyelination is a process continuing intomidlife,
ith thin intracortical axons among the last to be myelinated
able 1
n vivo techniques for APOE studies.
Modality Subtype Parameters
Magnetic resonance
imaging (MRI)
Cortical and subcortical morphometrya Regional volum
Diffusion tensor imaging (DTI)b Fractional anis
Mean diffusion
“Radial” and “a
Resting-state functional MRI (fMRI)c Between-netw
correlations in
blood-oxygen-
during “rest”; r
include the def
Task-related fMRI Relative chang
speciﬁc stimul
performance
Positron emission
imaging (PET)
Metabolic imaging Glucose metab
FDG)
Molecular binding Neurotransmit
Other molecul
Regional blood ﬂow Rate of water p
Behavior Intelligence Statistical facto
cognitive dom
Cognitive tests Domain-speciﬁ
etc.
Reaction time Speed and vari
inter-session v
a Automated methods for quantiﬁcation of regional cortical thickness have been develo
b DTI is sensitive to the directionality and degree of water displacement in biological t
3D model reﬂecting the magnitude and direction of water diffusion within each voxel
n elongated ellipsoid reﬂecting highly directional water diffusion and a sphere reﬂecting
oherence of the diffusion. “Axial” (AxD) and “radial” (RD) diffusion denote the length o
he degree of diffusion along and perpendicular to the longest axis of the ellipse, respect
hree axes in space, i.e. the estimated bulk of diffusivity irrespective of direction. Importan
ercignani, 2009), but RD is likely to be more sensitive to mechanisms restricting the di
elated to membrane and myelin integrity than AxD, which is likely to be more related to
c By investigating the spatiotemporal correlation patterns of the BOLD signal, resting-s
ifferent brain regions, and different analysis methods provide various indices of “functio
he understanding of the fundamental organization of the processing systems in the br
ncluding low-level sensorimotor and higher-order attention and cognitive control netw
n the absence of speciﬁc contextual demands, but show high correspondence with task
omparing functional brain network properties within or between groups where matchin
linical groups or across large age ranges), or even impossible (e.g. when comparing ac
ccurs preferentially throughout brain regions comprising the default mode network (DM
rocesses and memory decline (Buckner et al., 2008; Greicius et al., 2004).vioral Reviews 37 (2013) 1322–1335
(Bartzokis et al., 2012). In human autopsy samples, there is signiﬁ-
cant loss of thinner, latemyelinatingﬁber sheathswith age (Marner
et al., 2003). The brains of aged rhesus monkeys show signs of gen-
eral myelin degeneration, which correlates with cognitive decline,
but there is also evidence of active myelin repair (Peters and
Kemper, 2012;Peters andSethares, 2003). Thus, in thenormal aging
primate brain, developmental myelination, myelin degeneration
and remyelinationmay all occur. Remyelination is qualitatively dif-
ferent fromdevelopmentalmyelination (Fancy et al., 2011). During
development, the thickness of the myelin sheath is closely corre-
lated with axonal diameter, whereas in remyelination the sheath
is often inappropriately thin, which could cause reduced conduc-
tion velocity (Fancy et al., 2011; Peters and Kemper, 2012). Loss of
myelin may secondarily lead to axonal loss (Fancy et al., 2011).
Imaging techniques can be used to probe human white matter
structure in vivo (Table 1). Madden et al. (2009) have reviewed
the evidence that cognitive aging is related to white matter
integrity, and conclude that diffusion tensor imaging (DTI) shows
an age-related decline with an anterior to posterior brain gradi-
ent. Bartzokis et al. (2012) have suggested that certain MRI and
DTI parameters reﬂect speciﬁc changes in myelination. Transverse
relaxation rate (R2) and radial diffusivity (RD) show a general age-
related decline in late-myelinating regions (Bartzokis et al., 2012).
Interpretation
e, cortical thickness Regional atrophy, due to cell loss or other
causes
otropy Compromised white matter ﬁber integrity
xial” diffusion Myelin density and integrity. axonal density,
diameter and degeneration
ork or -voxel temporal
the
level-dependent (BOLD) signal
esting-state networks (RSNs)
ault mode network (DMN)
Increased or decreased cortical and
sub-cortical functional integration, altered
intrinsic network dynamics and RSN/DMN
functional connectivity
es in the BOLD signal during
ation, e.g. during memory task
Increased/decreased neuronal recruitment in
response to speciﬁc cognitive demands
olism (ﬂuoride-deoxyglucose – Reduced metabolic activity, due to
degenerative or molecular mechanisms
ter-speciﬁc receptor ligands Loss of receptors or reduced neurotransmitter
activity.
ar ligands (beta amyloid – PiB) Accumulation of pathological agents
erfusion (15O) Reduced neuronal activity or cerebrovascular
changes
r representing overlap between
ains
Brain function and integrity
c tasks of memory, attention, Regional cortical function/pathology
ability (mean, inter-trial or
ariability)
Reduced function in cortical networks
(slowness or instability)
ped by Dale, Fischl and co-workers (Fischl et al., 2002).
issues. By applying magnetic ﬁelds in different directions it is possible to estimate
, from which various parameters can be derived. The 3D model is ellipsoidal, with
equal diffusion in all directions. Fractional anisotropy (FA) reﬂects the directional
f the largest and second largest eigenvalue of the ellipsoid, usually interpreted as
ively. Mean diffusion (MD) represents the average magnitude of diffusion along all
tly, the biological speciﬁcity of the DTI indices is not clear (Wheeler-Kingshott and
ffusion across rather than along the axons, and is thus thought to be more closely
axonal integrity and damage (Budde et al., 2009).
tate fMRI targets the “intrinsic” (in contrast to “evoked”) functional integration of
nal connectivity” (FC; Margulies et al., 2010). Resting-state FC (RSFC) has promoted
ain, and has revealed speciﬁc functional neuronal networks (Biswal et al., 1995),
orks (Zhang and Raichle, 2010). Such resting state networks (RSNs) are identiﬁable
-evoked networks (Smith et al., 2009). RSFC may be particularly useful for studies
g of cognitive task performance is a challenge (e.g. when comparing subjects across
ross species or subjects of different levels of consciousness). Since AD pathology
N), an intriguing hypothesis is that intrinsic DMN metabolism is related to disease
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.1.2. APOE genotype and myelination
Given that cholesterol is an essential component of myelin,
nd ApoE is the most abundant cholesterol transporter in the CNS
Bu, 2009; Holtzman et al., 2012), it is of considerable interest to
etermine whether APOE genotype affects myelination status. In
tudies of healthy individuals aged 55–76, the MRI R2 parame-
er, which is thought to indicate myelin integrity, was signiﬁcantly
ower in older carriers of the APOE *E4 allele and was associated
ith reduced cognitive processing speed in *E4 carriers (Bartzokis
t al., 2006, 2007). These ﬁndings are consistent with the hypothe-
is thatmyelin repair is less efﬁcient in *E4 carriers (Bartzokis et al.,
007).
.2. Mitochondrial function
Several mechanisms have been proposed by which ApoE may
mpair mitochondrial function (Mahley et al., 2006; Mahley and
uang, 2009).Mitochondrial alterations causedbyneurotoxicApoE
4 fragments may be an important amyloid -independent neu-
opathological mechanism involving the *E4 allele.
In a study of autopsy brain tissue from the posterior cin-
ulate cortex of 15 young *E4 carriers and 25 controls, Valla
t al. (2010) found reduced cytochrome oxidase activity indica-
ive of mitochondrial dysfunction in the *E4 carriers. The ﬁndings
ere unrelated to amyloid  or tau. Gene expression proﬁling
f post-mortem cortical brain tissue from 13 *E4 carriers and
8 non-carriers of mean age 42 years revealed that biological
athways involved with among others mitochondrial function
ere affected in the *E4 group (Conejero-Goldberg et al., 2011).
here were also regional differences in expression of APOE itself,
ith higher expression in regions more vulnerable to Alzheimer
athology. The brains analyzed were free of plaque and tangle
athology.
.3. Cholinergic functions
.3.1. Effect of aging on the cholinergic system
Reduced nicotinic receptor availability has been reported in
ormal aging (Mitsis et al., 2009). The structure of the human
asal forebrain cholinergic system can be analyzed in vivo using
RI and DTI (Grothe et al., 2010, 2012; Teipel et al., 2011). In a
tudy of >200 cognitively normal subjects (20–94 years), Grothe
t al. (2012) found a linear age-related shrinkage of the basal
orebrain beginning in young adulthood. There is evidence that
ge-related cholinergic dysfunction is mediated mainly by mech-
nisms including decreased cellular function, lower brain choline
ptake, neuronal shrinkage, axonal degeneration, and synaptic loss,
ather than deﬁnite cell loss (Schliebs and Arendt, 2011). In a
ost-mortem study of 14 neurologically healthy individuals, Tohgi
t al. (1998) found an age-related decrease in nicotinic receptor
RNA expression in cortex and hippocampus. In the cortex there
s regional variation in the density of cholinergic ﬁbers, as shown
y immunohistochemistry, with especially high ﬁber density in the
ippocampus (Geula and Mesulam, 1996).
.3.2. ApoE and cholinergic functions
In addition to a general neurotoxic effect of ApoE fragments,
here is evidence from animal studies that ApoE peptides specif-
cally impair cholinergic functions (Mahley et al., 2006; Verghese
t al., 2011). Peptides derived from the LDLR-binding domain of
poE block the function of nicotinic acetylcholine receptors in
at hippocampal slices (Klein and Yakel, 2004). Direct infusion
f the same ApoE peptides into the ventral hippocampus of rats
aused signiﬁcant cognitive impairment in radial-arm maze learn-
ng that persisted for several weeks (Eddins et al., 2009). Siegel
t al. (2011) found that Apoe−/− knockout mice had fewer corticalvioral Reviews 37 (2013) 1322–1335 1325
and hippocampal muscarinic acetyl choline receptors compared to
wild-type animals.
Allen et al. (1997) found that choline acetyltransferase activity
in post-mortem brain tissue from cognitively normal persons was
lower in *E4 carriers. The ﬁndings were signiﬁcant for temporal
cortex and were independent of the presence of senile plaques.
Cognitive studies in healthy normal controls have indicated that
APOE genotype interacts with allelic variation in a cholinergic gene
(CHRNA4) to inﬂuenceattentionperformance (Espesethet al., 2006;
Reinvang et al., 2010a).
2.4. Vascular function
A meta-analysis of blood–brain-barrier permeability showed
that neurologically healthyhumanshadanage-dependent increase
in vascular permeability (Farrall and Wardlaw, 2009). Disruption
of the blood–brain-barrier function can lead to defective reg-
ulation of cerebral blood ﬂow (CBF) with further pathological
consequences (Zlokovic, 2011). Normal aging diminishes brain cir-
culatory functions, including a detectable decay of CBF in the limbic
and association cortices that has been suggested to underlie age-
related cognitive changes (Martin et al., 1991).
In transgenic mice with human APOE *E4 instead of the endoge-
nous Apoe gene, the ApoE 4 protein stimulates an inﬂammatory
pathway in pericytes surrounding brain capillaries (Bell et al.,
2012). Even in very young animals, the brain vasculature was
damaged, the integrity of the blood–brain barrier was reduced
and CBF was lower. These changes were followed by neuronal
and synaptic dysfunction and neurodegeneration. Although these
ﬁndings highlight an amyloid-independent mechanism by which
APOE *E4 can trigger vascular pathology and neurodegeneration,
*E4 does not inevitably cause neuropathology in humans, so fur-
ther work is needed to determine the relevance of this pathway in
man.
APOE genotype is associatedwith different forms of cerebrovas-
cular disease and cerebrovascular risk factors in epidemiological
studies. In an imaging study of nearly 4000 individuals aged 45
and up without dementia from the general population, Poels et al.
(2010) found that the prevalence of asymptomatic microbleeds
gradually increased with age. Deep or infratentorial microbleeds
were associated with cardiovascular risk factors, lacunar infarcts
and white matter lesions, while lobar microbleeds were associ-
ated with APOE *E4 and diastolic blood pressure. Zade et al. (2010)
carried out neuropsychological testing of 1995 participants (mean
age 61) from the Framingham Heart Study and found that the
*E4 allele exacerbates the effects of cerebrovascular risk factors
on neuropsychological function. Systolic blood pressure was the
only individual risk factor signiﬁcantly linked to cognitive mea-
sures.
3. Non-pathological effects of APOE genotype on cognition
and imaging
APOE *E4 interacts strongly with speciﬁc age-associated
pathogenic factors, most signiﬁcantly with amyloid  accumula-
tion. The effects of APOE genotype can be assessed independently
of amyloid  by studying individuals in an age range where amy-
loid  accumulation is absent or infrequent, and therefore unlikely
to bias the results. When participants are below the age of 50, one
can be conﬁdent that there is no or minimal inﬂuence of early AD
pathology and amyloid  burden remains relatively low even in
*E4 carriers until the early 60s (Morris et al., 2010). We therefore
review studies selectively and focus mainly on the age range up to
about 65.
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Findings from speciﬁc task-related fMRI studies are beyond the
scope of the present overview, and we refer interested readers326 I. Reinvang et al. / Neuroscience and B
.1. APOE-related effects on cognition
Bloss et al. (2008) used a test of educational achievement to
tudy 109 children aged 11–16. Information was collected from
arents about family history of dementia: no main effect of APOE
enotype alone or family history alone was found but *E4 carriers
ith a family history of AD did signiﬁcantly worse in tests of read-
ng, language and ﬁgure copying. Taylor et al. (2011) investigated
ssociationsbetweenAPOEgenotypeandplasma lipids (at age9), IQ
at age 8), memory (at ages 8 and 10), and performance in school
ttainment tests (at ages 7, 11, and 14) in nearly 6000 children.
lthough APOE genotype was strongly associated with lipid levels,
here were no signiﬁcant associations with intelligence, memory
r school attainment.
In a community sample of 220 individuals with a mean age of
6 years (range 24–60), Flory et al. (2000) found that *E4 carriers
erformed signiﬁcantly worse than *E2 or *E3 carriers in tests of
earning and memory. The ﬁndings held after adjustment for age.
he study by Jorm et al. (2007) is important by virtue of its high
umber of participants (N=6560) in three separate age cohorts
20s, 40s and 60s). No effect of APOE genotype was found on either
pisodic memory, attention or reaction time in any age group.
hen the oldest group was followed up 4 years later, develop-
ent of MCI was not related to *E4 carrier status, but *E4 had some
nﬂuence on cognitive declinewhen interactionwith head injury or
remorbid intelligence was taken into consideration (Christensen
t al., 2008).
Mondadori et al. (2007) studied the effect of APOE genotype on
memory test in 340 young participants (mean age 23 years), 34 of
homperformed the test in an fMRI session. *E4 carriers performed
etter than *E3 carriers, and also showed lower activation levels in
emory-relevant areas of the brain during task performance. In
study of two groups of healthy subjects aged 45–60 and 61–79,
einvang et al. (2010a) found no effect of APOE genotype on cogni-
ive function at baselineor on cognitivedecline after 3.5 years in the
ounger group. However, there was evidence that APOE genotype
nteracted with variants in CHRNA4 (cholinergic receptor neural
icotinic alpha chain 4) to affect decline in attention and memory.
his interaction was mostly independent of age.
Caselli et al. (2009) carried out a longitudinal study of an *E4-
nriched cohort with familial risk of AD covering a wide age-range.
sing growth-curve modeling combining cross-sectional and lon-
itudinal data, they concluded thatmemory test performance in *E4
omozygotes starts to deviate from non-carriers prior to age 60. In
separate study of 10 individuals with declining memory and 15
on-decliners Caselli et al. (2008) found that reduced metabolic
ate, determined by ﬂuoride-deoxyglucose (FDG)-PET (Table 1),
redates cognitive decline by 3–4 years.
Some studies have focused explicitly on experimental cogni-
ive tasks of attention and working memory. In a longitudinal
tudy of middle-aged and young-old individuals, Greenwood et al.
2000)) found that *E4 carriers showed greater decline in a visual
ttention test. However, 78% of the participants had ﬁrst degree
elatives with AD, so this sample is likely to be biased toward indi-
iduals with incipient dementia. Other work by Greenwood et al.
2005) revealed deﬁcits in visual attention and working memory
n *E4 carriers, but the study group had a signiﬁcant proportion of
lder participants. Espeseth et al. (2012) combined structural MRI,
vent-related potentials and attention measures in a middle-aged
roup (mean age 62) and found that *E4 affects cortical thick-
ess of critical nodes in brain attentional networks. Rosen et al.
2002) reported that middle-aged *E4 carriers performedworse on
workingmemory task requiring divided attention. Reinvang et al.
2010b) conﬁrmed a working memory deﬁcit, but only in male *E4
omozygotes. *E4 carriers did not exhibit episodicmemory deﬁcits
n either of these studies.vioral Reviews 37 (2013) 1322–1335
3.1.1. Summary and conclusion of cognitive studies
In conclusion, evidence for non-pathological APOE-related
deﬁcits in cognition is sparse and conﬂicting. A largemeta-analysis
found evidence for memory deﬁcits in *E4 carriers (Wisdom
et al., 2011), but many of the studies analyzed may have involved
middle-aged and old persons at different stages of prodromal AD.
It remains an intriguing possibility that *E4 may be associated
with subtle deﬁcits in speciﬁc measures of attention or working
memory.
3.2. APOE-related non-pathological effects determined by MRI
imaging
3.2.1. Resting-state functional MRI and functional connectivity
Filippini et al. (2009) studied 18 *E4 carriers, aged 20–35, and
matched controls and reported a higher degree of default-mode
network (DMN) co-activation in carriers. Therewere no differences
in gray matter volume. The pattern of increased DMN integra-
tion during rest in healthy *E4 carriers was recently replicated and
extended to a sample ofmiddle-aged and elderly subjects (Westlye
et al., 2011). *E4 carriers showed evidence of increased coupling
between thehippocampusand theposteriorDMN,whichwas taken
to reﬂect a relative failure todecouple thehippocampusduring rest.
In support of this, the degree of hippocampal DMN coupling cor-
related inversely with memory performance, i.e. higher coupling
was related to poorer memory performance (Westlye et al., 2011).
Sheline et al. (2010) studied resting state connectivity with fMRI
in 100 healthy persons of mean age 62 years, who were free of
amyloid plaques as judged by PET. *E4 carriers showed an altered
pattern of connectivity, predating any cognitive decline, from the
precuneus to the hippocampus and temporal lobe regions, which
are also involved in AD pathology.
Trachtenberg et al. (2012b) recently performed a similar analy-
sis on 10 different resting-state networks (RSNs), including medial
and lateral visual, sensorimotor, auditory, DMN, an “executive con-
trol network”, right and left frontoparietal networks, and anterior
and posterior hippocampal networks in 77 healthy subjects aged
32–55 years. APOE genotype affected the anterior and posterior
hippocampal networks, the auditory network, and the left fron-
toparietal network. Intriguingly, functional integrationwas similar
in *E2 and *E4 carriers, but both groups differed signiﬁcantly from
*E3 homozygotes. The authors concluded that in healthy adults,
APOE genotype affects the differentiation of functional brain net-
works independently of the APOE-related increased risk of AD, and
may instead reﬂect a functional role of different ApoE isoforms
during neurodevelopment.
Using seed-based analyses, Machulda et al. (2011) studied
connectivity in the DMN and the “salience” network (a net-
work assumed to be inversely correlated with DMN and showing
intensiﬁed connectivity in AD), and found altered connectivity in
56 cognitively normal *E4 carriers relative to 56 matched non-
carriers. Speciﬁcally, a seed in the posterior cingulate revealed
decreased functional connectivity in regions of the posterior DMN
including the left middle temporal gyrus, left inferior parietal lob-
ule, and bilateral anterior temporal lobules. In contrast, a seed
in the anterior cingulate revealed increased functional connec-
tivity in the “salience” network including the cingulate, insula,
medial prefrontal cortex, striatum, and thalamus (Machulda et al.,
2011). Importantly, the participants were all above age 70 and
it is unclear whether the ﬁndings generalize to younger popula-
tions.to previous excellent reviews (Bookheimer and Burggren, 2009;
Trachtenberg et al., 2012c).
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.2.2. Fiber integrity and structural connectivity
The consistent observations of alterations in patterns of func-
ional connectivity (FC) in *E4 carriersmay be indicative of changes
n white matter microstructural integrity. A number of DTI studies
ave documented decreased diffusion anisotropy in *E4 carriers
Heise et al., 2011; Honea et al., 2009; Nierenberg et al., 2005;
ersson et al., 2006), possibly indicating less coherent ﬁber archi-
ecture or altered microstructural integrity. Heise et al. (2011)
ompared younger (age 20–35) with older (age 50–78) subjects
nd observed a complex pattern of effects of APOE genotype in
he two groups, but concluded that there was no evidence of age
roup by APOE interactions on any of the DTI measures. Previous
eports converge on reduced white matter diffusion anisotropy in
E4 carriers, but Bendlin et al. (2010) reported no main effect of
POE genotype on FA, MD or any of the tested DTI parameters in
large sample (N=136) of healthy middle-aged volunteers (mean
ge 55–60), including 56 *E4 carriers. However, an effect of *E4was
ound in participants with a family history of AD. Recently, Brown
t al. (2011) compared graph-theoretical indices of structural con-
ectivity derived fromDTI tractographymeasures in a sample of 25
arriers (mean age 60.8, SD=9.7 years) and 30 non-carriers (mean
ge: 63.8, SD=8.3 years) of the *E4 allele. Relative to non-carriers,
E4 carriers showed evidence of accelerated age-related loss in
mall-worldness with age, which was taken to reﬂect a loss in the
alance between global integration and local modularity of infor-
ation processing (Brown et al., 2011). Interestingly, *E4 carriers
ere found to exhibit accelerated age-related loss in local intercon-
ectivity among regions comprising theDMN(Buckner et al., 2008),
hich corroborates evidence reviewed above of altered DMN con-
ectivity in *E4 carriers (Filippini et al., 2009;Machulda et al., 2011;
estlye et al., 2011).
In summary, DTI studies have produced conﬂicting evidence
f the role of APOE genotype as a modulator of white matter
icrostructure in healthy subjects. Most studies have been per-
ormed on middle-aged and elderly volunteers, where the risk of
onfounding effects of incipient neurodegenerative disease is high,
nd little is knownabout the timing of the effects, i.e.whetherAPOE
enotype has alreadymodulatedwhitemattermicrostructure dur-
ng neurodevelopment, orwhether the effects aremainly operating
y accelerating the rate of aging. In a recent study (Westlye et al.,
012) studied a larger (N=203) healthy sample than previously
eported with a wide age distribution (21–70 years) and showed
n age-independent increase in radial diffusivity in *E4 carriers
Fig. 1). Interestingly, similar changes were observed in *E2 car-
iers, suggesting that the effect of APOE genotype on white matter
icrostructure is independent of its effect on AD risk. The gen-
ral observation that genotypic effects do not directly reﬂect the
isk of AD is also supported by recent functional imaging studies
Trachtenberg et al., 2012a, 2012b).
.2.3. Cortical morphology
In a recent structural MRI study of 269 neonates, Knickmeyer
t al. (2013) observed decreased graymatter volume in the tempo-
al lobes, including the hippocampus, and increased parietal lobe
olumes in *E4 heterozygous babies compared to *E3 homozy-
otes.Whereas these intriguing results suggest that effects of APOE
n brain structure are already present at or even before birth,
ost of the available evidence comes from studies of adult sam-
les. In a study including 239 healthy children, adolescents and
oung adults (age 8–20), Shaw et al. (2007) found that the left
ntorhinal region was thinnest in *E4 carriers, intermediate in *E3
omozygotes and thickest in *E2 carriers. Many of the partici-
ants underwent multiple scans and the neuroanatomical effects
f APOE genotype seemed to be ﬁxed over the age-range exam-
ned. Fennema-Notestine et al. (2011) studied a large group of
ealthy 50–59 year olds and found reduced cortical thickness invioral Reviews 37 (2013) 1322–1335 1327
frontal but not in temporal regions in *E4 carriers. Using amodel of
regional covariance in regional gray matter volume as estimated
using voxel-based morphometry (VBM), Alexander et al. (2012)
found a pattern of gray matter reduction in *E4 carriers (N=14,
age 26–45) involving bilateral frontal, anterior cingulate, parietal,
and lateral temporal cortices with correlated volume increases in
the hippocampal region. Bunce et al. (2012) studied 314 healthy
participants aged 44–48 and found no effect of *E4 on the volume
of entorhinal cortex, medial temporal lobe or temporal neocortex.
Other brain regions were not investigated.
In a study of morphometric variation inmiddle-aged and older-
age individuals, Espeseth et al. (2008) found that middle-aged *E4
carriers had a thicker cortex than non-carriers in several frontal
and temporal areas in both hemispheres, but showed a steeper
age-related decline in adjacent areas. Upon comparison of the *E4-
speciﬁc age-related thinning with previously published patterns
of thinning in normal aging and AD, they concluded that *E4 may
function to accelerate thinning in areas found to decline in nor-
mal aging (medial prefrontal and pericentral cortex), but also to
initiate thinning in areas associated with AD and amyloid  aggre-
gation (occipitotemporal and basal temporal cortex). A follow up
study by Espeseth et al. (2012) showed that cortical thickness in
selected regions was associated with attention performance and
amplitude of attention-related ERP (event-related potential) com-
ponents. Chen et al. (2007) studied healthy cognitively normal
persons aged 47–68 with repeated morphometric MRI scans. *E4
homozygotes showed an accelerated rate of brain atrophy while
remaining cognitively normal. All participants in this study had
a ﬁrst degree relative with AD, which is likely to have an impor-
tant impact on the results (Donix et al., 2012). Donix et al. (2010)
studied 32 cognitively intact subjects (16 APOE *E4 carriers and
16 non-carriers, mean age 61 years) who underwent baseline and
follow-up MRI scans. Over the course of two years there was sig-
niﬁcantly greater cortical thinning in the subiculum and entorhinal
cortex of *E4 carriers compared to non-carriers. Average cortical
thinning across all medial temporal lobe subregions combinedwas
also signiﬁcantly greater in *E4 carriers.
In summary, several studies reviewed above converge on a sig-
niﬁcant impact of APOE on brainmorphology. The evidence further
suggests that the effects may already be present at birth, and that
APOE may also modulate the rate of brain aging. However, many
morphometric studies of healthy adults are marred by small sam-
ples, and selective reporting is likely to have produced a biased
impression. Further, *E4 is likely to interact with other pathological
factors, making it hard to isolate the unique genetic effect. Interest-
ingly, the ENIGMA consortiumperformed ameta-analysis of GWAS
studies in cognitively normal samples, focusing on hippocampus
volume, intracranial volume and whole brain volume of more than
5700 cognitively normal participants. Importantly, APOE genotype
didnot emergeas strongly associatedwithanyof the includedbrain
parameters (Stein et al., 2012). Thus, ﬁndings of reducedhippocam-
pal volume reported in several earlier studies (Cherbuinet al., 2007)
may be caused by inclusion of older persons with pathology.
3.2.4. Summary and conclusion of MR studies
MR ﬁndings (structural MRI and DTI) point to changes in white
matter integrity and brain connectivity associated with *E4, possi-
bly through myelin and lipid metabolism. There is some evidence
that morphometric changes such as reduced hippocampal vol-
ume or entorhinal cortex thickness occur early in life, but a recent
large-scale GWAS study questions this ﬁnding. Recent studies with
relatively high numbers of middle-aged participants point to an
association between *E4 and changes in the frontal rather than the
temporal lobe. Findingsmay have been affected by selection of par-
ticipants according to familial ADor history of brain injury. It can be
assumed that these results are not strongly inﬂuenced by presence
1328 I. Reinvang et al. / Neuroscience and Biobehavioral Reviews 37 (2013) 1322–1335
Fig. 1. APOE effects on diffusion tensor imaging. The left panel shows voxels (in red) with signiﬁcantly (p<0.05, corrected) increased radial diffusion (RD) in individuals with
the APOE *E3/*E4 genotype compared with individuals with the *E3/*E3 genotype. The numbers refer to the corresponding Montreal Neurological Institute brain template z
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f amyloid , either because it has been explicitly controlled for or
ecause of the relatively young age of participants.
.3. APOE effects on FDG-PET
Reiman et al. (2004) studied glucose metabolism in 12 *E4 het-
rozygotes and controls aged 20–30 with FDG-PET (Table 1) and
ound a pattern of regional hypometabolism similar to that in
atients with AD, including bilaterally in the posterior cingulate,
arietal, temporal, and prefrontal cortices. There was consider-
ble overlap between groups, and the *E4 carrier group was small
N=13). In the absence of atrophy, this ﬁnding is consistent with
itochondrial dysfunction in *E4 carriers. Another study (Scarmeas
t al., 2003) conﬁrmed reduced temporal lobe perfusion in young
E4 carriers, but included only 3 carriers.
. Effects of APOE genotype in prodromal and early AD
The role of APOE genotype in AD and other neurodegenerative
isordershasbeenextensively reviewed (Bu, 2009;Kimet al., 2009;
erghese et al., 2011). The consensus is that the differential effects
f ApoE isoforms on amyloid  aggregation and clearance play a
ajor role in AD pathogenesis. The *E4 allele may cause a gain of
oxic function in theApoEprotein, or a loss of neuroprotective func-
ion, or both. In vivo imaging of ligands that bind to pathological
rotein deposits, such as PiB which binds to amyloid  plaques
Table 1), hasmade it possible to distinguish betweenprobable pre-
linicalADandother age-related conditions. Evidence fromPiB-PET
maging and autopsy studies indicate that amyloid accumulation
ay take place in the late forties or earlier in cognitively normal
ndividuals (Braak and Braak, 1997; Kok et al., 2009; Rowe et al.,
010).
The cascademodel of AD proposed by Jack et al. (2010) points to
evelopment and accumulation of amyloid  oligomers as the ear-
iest event in AD pathophysiology, followed by tau accumulation
ccurring up to 20 years before diagnosis, whereas brain atro-
hy measured by MRI and cognitive changes are late events that
ccur 2–5 years before diagnosis. These mechanisms are assumed
ounfold in a causal sequencewith relatively little overlap between
hases; thus amyloid and tau accumulation is the cause of subse-
uent brain atrophy and cognitive and clinical decline, but further
ccumulation has no direct role in determining the rate of pro-
ression of degeneration and cognitive impairment. A key question
rising from this model is whether the effect of APOE genotype can
e accounted for solely by its inﬂuence on amyloid accumulation,
r if it has an independent role in inﬂuencing imaging, cognitive and
linical phenotypes.ide of the brain. The right panel shows radial diffusion values against age and APOE
signiﬁcant interaction of APOE genotype and age.
Herrup (2010) takes a broader view in which several age-
associated pathological factors may initiate a pathological course.
Factorswhich reduce clearance of amyloid from thebrain, such as
the 4 isoform of the ApoE protein, initiate a chronic inﬂammatory
response which leads to further deposition of amyloid. APOE geno-
type also has an impact on the brain vascular system (Poels et al.,
2010), and the ApoE 4 protein causes vascular pathology in mice
(Bell et al., 2012). Since the ﬁrst step of Herrup’s model involves
an initiating injury, APOE genotype might act independently to
increase the probability that the initiating injury is vascular in
nature. This would lead to a higher frequency of vascular compo-
nents in subsequent clinical AD in *E4 carriers, as has been reported
by Thal et al. (2010).
4.1. Amyloid accumulation and clearance
The three common isoforms of ApoE differ profoundly in struc-
ture and function (Mahley et al., 2006) including their ability to
interact with amyloid . Increasing *E4 dose is associated with
reduced clearance and increased accumulation of amyloid . In
the early stages of amyloid deposition, cortical areas and/or layers
that are sparsely myelinated have denser amyloid deposits than
those rich in myelin. Cognitively normal APOE *E4 carriers show
increased uptake of the amyloid-binding ligand PiB (Morris et al.,
2010; Reiman et al., 2009) and the amyloid- and tau-binding lig-
and FDDNP (Small et al., 2009) when compared to non-carriers. In
a PiB-PET study of 135 cognitively normal persons of mean age 75
years, 65%of PiB-positive individualswere *E4 carriers compared to
24% of the PiB–negative subjects (Storandt et al., 2009). Concurrent
cognitive performance was unrelated to amyloid  levels but was
related to regional brain volumes with the exception of the cau-
date. Kantarci et al. (2012) found that whereas amyloid  load is
associated with greater cognitive impairment in APOE *E4 carriers,
cognitive function in non-carriers is inﬂuenced less by the amy-
loid  load, suggesting that ApoE isoforms modulate the harmful
effects of amyloid  on cognitive function. Vlassenko et al. (2011)
did a follow-up PiB study of 246 subjects who were initially cogni-
tively normal and found that *E4 carriers had an increased plaque
burden of 8% per year andwere at greater risk of converting to PiB-
positive status. Kok et al. (2009) studied an autopsy series of 603
community-dwelling persons and found that while senile plaque
density was strongly related to APOE *E4 carrier status in every age
group, themostmarked contrast to *E3/*E3was found in the 50–59
age group. It is not clear at present if ApoE 4 plays a role in the ini-
tial formation of amyloid , or just accelerates the rate of amyloid
 formation once the process has started, but the studies of Morris
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t al. (2010) and Vlassenko et al. (2011) suggest that both may be
he case.
.2. Amyloid ˇ and brain structure
As mentioned above, PiB-PET imaging has made it possible
o study the early effects of amyloid  accumulation in vivo.
bnormal brain levels of amyloid  are also reﬂected indirectly
n cerebrospinal ﬂuid (CSF) concentration, with low levels in CSF
ndicating cerebral accumulation of amyloid  as measured with
iB (Tolboom et al., 2009).
In healthy volunteers over 60 years of age, Pike et al. (2011)
ound twice the incidence of APOE *E4 in PiB-positive participants.
n a sample covering the clinical range from healthy controls to
D, Vemuri et al. (2010a) found that at baseline, *E4 dose was
redictive of amyloid levels in CSF, but less so of ventricular atro-
hy as determined by MRI. At follow-up, however, *E4 predicted
reater annual increase in ventricular volume in patients withMCI,
ut did not predict change in CSF amyloid  levels (Vemuri et al.,
010b). Chetelat et al. (2011) reported that hippocampal atrophy
ndPiB retention in temporalneocortexcontributed independently
o memory function in non-demented, amyloid -positive indi-
iduals. Sperling et al. (2009) found that high levels of amyloid
eposition were associated with aberrant DMN activity in asymp-
omatic and minimally impaired older individuals, similar to the
attern of dysfunction reported in AD patients. Some *E4-related
eﬁcits in resting state connectivity may have been present prior
o or independently of amyloid deposition (Sheline et al., 2010).
Tosun et al. (2010) found that the relationship between CSF
iomarkers, APOE *E4 status and brain atrophy rates is regionally
peciﬁc. In individualswithMCI, CSF biomarker concentrations (i.e.
ower amyloid , higher tau markers) and APOE *E4 were indepen-
ently associated with higher rates of ventricular enlargement and
issue volume loss bilaterally in the hippocampus and several other
egions. Similarly, lower CSF amyloid -42 and *E4 together were
ssociated with higher rates of cortical thinning in temporopari-
tal cortex, including precuneus and posterior cingulate. In a study
f both cognitively normal and memory-impaired participants,
hiang et al. (2011) found that baseline CSF amyloid  predicted
rogression of hippocampal volume loss in all groups, andAPOE *E4
as independently associated with volume loss. However, APOE
E4 acted synergistically with amyloid to amplify the degree of
eurodegeneration in MCI. In an MRI study focussing on change in
ippocampal volume over 6–12 months, Schuff et al. (2009) found
hat MCI and AD groups showed accelerated loss compared to nor-
al individuals over 1 year. *E4 was associated with a higher rate
f volume loss and smaller baseline volume irrespective of sever-
ty of cognitive symptoms, but there was no dose effect of *E4. CSF
myloid  was correlated with MRI only in the group classiﬁed
s having MCI. In a study including both regional PiB measures
f amyloid load and MRI measures of atrophy, Jack et al. (2008)
ound variable relationships. The frontal lobes had high PiB reten-
ion with little gray matter loss, anteromedial temporal areas had
ow PiB retention with signiﬁcant gray matter loss, whereas lateral
emporoparietal association cortex displayed both signiﬁcant PiB
etention and gray matter loss. This study did not include *E4 as a
ariable.
The studies cited above reﬂect complex relationships between
myloid  load, cerebral morphometric variables and cognition,
hich are further modulated by the clinical status of the partici-
ants. However, indications are thatAPOE *E4, in addition to having
n impact on amyloid load, affects brain structure either indepen-
ently of (Chiang et al., 2011; Schuff et al., 2009; Tosun et al., 2010;
emuri et al., 2010a) or synergistically with (Chiang et al., 2011;
osun et al., 2010) amyloid  load.vioral Reviews 37 (2013) 1322–1335 1329
4.3. Pre-dementia clinical phenotypes
Several studies show that *E4 carriersmay have different cogni-
tive or neurodegenerative clinical proﬁles to non-carriers.APOE *E4
is associated with risk of the amnestic (memory impairment) form
ofMCI, but notwithother subtypes (Brainerd et al., 2011).Wolk and
Dickerson (2010) examined if APOE genotype was associated with
a speciﬁc cognitive phenotype in mild AD and found that *E4 carri-
ers showed poorer memory retention and greater medial temporal
lobe atrophy while non-carriers were more impaired on tests of
working memory and executive control, and had more frontopari-
etal atrophy. In a comparative study of amnestic and non-amnestic
MCI subtypes, He et al. (2009) found that APOE *E4 carriers were
twice as prevalent in the amnestic group. In a study of memory
clinic patients (mean age 54–64 in different subgroups), CSF levels
ofpathologicalmarkerswerecorrelatedwithmemoryperformance
in *E4 carriers but not in non-carriers (Andersson et al., 2007).
Some studies have examined both regional cerebral blood ﬂow
(rCBF) and MRI brain morphometry in MCI. (Luckhaus et al., 2010)
found that hippocampal but not amygdalar volumewas associated
with one or two *E4 alleles in MCI andmild AD, while there was no
association of *E4 with rCBF. They concluded that their data sup-
ports earlier indications that rCBF and regional volume changes are
at least partly dissociated in the early pathogenesis of AD, and het-
erogeneously associated with *E4. In contrast, Thambisetty et al.
(2010) found in a longitudinal study that cognitively normal *E4
carriers showed hypoperfusion several years before developing
MCI. Wierenga et al. (2012) found that CBF was elevated in the
parahippocampal/fusiform gyrus in cognitively normal *E4 carri-
ers but decreased in *E4 carriers with MCI. The opposite pattern
was seen in frontal regions.
It iswell documented that conversionofMCI toAD is accelerated
by APOE *E4 (Drzezga et al., 2005; Rowe et al., 2010; Schuff et al.,
2009). APOE genotype has a clear effect on the rate of amyloid 
accumulation and rate of atrophy of brain structures as reviewed
above. Other APOE-related factors may also inﬂuence clinical pro-
gression or phenotypic expression,most importantly cholinergic or
cerebrovascular functions. These additional effects of APOE geno-
type may accelerate disease progression and bias the clinical MCI
phenotype toward an amnestic type.
4.4. Clinical cholinergic mechanisms
In AD patients, APOE genotype affects the cholinergic system
in an allele-speciﬁc manner, such that *E4 is associated with
decreasedneuronal activity in thenucleusbasalis ofMeynert (nbM;
Salehi et al., 1998) and reduced choline acetyltransferase activity
in the cortex and hippocampus compared with *E2 and *E3 (Lai
et al., 2006; Poirier et al., 1995). In AD the activity of the nico-
tinic42 receptor is altered both in terms of reduced binding and
subunit expression (Burghaus et al., 2000; Martin-Ruiz et al., 1999,
2000), and reducednicotinic receptor availabilityhasbeen reported
in MCI (Terriere et al., 2010). Discrete reductions in uptake were
found in the medial temporal cortex. Kadir et al. (2006) used PET
molecular imaging to show that mean 11C-nicotine binding in the
frontal and parietal cortices of mild AD patients is associated with
performance in neuropsychological assessments of attention but
notmemory. Using probabilistic maps of the cholinergic structures
in the basal forebrain, Grothe et al. (2010) found that the volume
of the nbM was signiﬁcantly reduced in MCI patients. In addition,
volumes of different magnocellular compartments correlated sig-
niﬁcantly with regional gray matter atrophy in regions known to
be affected by AD. This is consistent with the ﬁnding that AD brains
show cell loss in the nbM complex, with the greatest loss in the
posterior section of the nbM. This section innervates the temporal
cortex, which shows marked loss of cholinergic ﬁber density in AD
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Geula andMesulam, 1996). Haense et al. (2012) used PET to study
cetylcholinesterase activity in MCI and found that the temporal
obemanifestation of cholinergic impairment is prominent at early
tages of dementia and is signiﬁcantly related to verbal and non-
erbal memory, language comprehension and executive function.
all et al. (2008) searched for presymptomatic markers in asymp-
omatic subjects who later developed AD, and observed atrophy of
he basal forebrain as long as 4.5 years before symptom onset.
These studies show that changes in cholinergic brain structures
nd receptor functions are found in early stages of dementia (MCI),
nd are correlated with cognitive functions. Most clinical studies
ave not includedAPOE genotype as amoderator, possibly based on
he view that cholinergic deﬁcit is only found in advanced demen-
ia. The studies cited above contradict this view.
.5. Vascular disease and vascular dementia
Cerebrovascular disease in the aged brain may take the form of
erebral atherosclerosis, small vessel disease or cerebral amyloid
ngiopathy (CAA; Grinberg and Thal, 2010). Whereas APOE *E4 as
risk factor for atherosclerosis is characterized by Grinberg and
hal (2010) as controversial, an association of *E4with risk of small
essel disease has been reported (Yip et al., 2005). Thal et al. (2002)
escribe two types of CAA: type1 is characterizedby amyloid depo-
ition in cortical capillaries, while type 2 exhibits amyloid deposits
n leptomeningeal and cortical vessels, with the exception of corti-
al capillaries. The frequency of the *E4 allele is more than 4 times
reater in CAA type 1 than in CAA type 2 cases and controls. In
ess advanced stages, CAA may lead to blood ﬂow changes without
issue damage (Thal et al., 2009). The sporadic form of CAA with
apillary deposits of amyloid  is strongly associated with AD and
POE *E4. Thal et al. (2010) state that AD cases with capillary CAA
iffer signiﬁcantly from other AD cases both genetically and mor-
hologically, thereby pointing to a speciﬁc capillary CAA-related
nd APOE E4*-associated subtype of AD.
In an autopsy series of cognitively normal persons aged 60 years
nd older, Caselli et al. (2010) found that *E4 was associated with
ncreased plaque burden and increased CAA in all brain subregions.
oneset al. (2011) studied selectedcandidategenes, includingAPOE,
s risk factors for vascular dementia, a heterogeneous condition
aused by reduced brain blood supply. In autopsy-conﬁrmed cases,
n association was found between APOE *E4 and mixed dementia
AD with concurrent cerebrovascular disease). Concurrent cere-
rovascular disease (in the form of infarcts) is found in 40% of
atientswithAD, but the incidenceofCAA inAD is evenhigher (Thal
t al., 2010). In a population-based study in which the Petersen
riteria of MCI were applied (Petersen et al., 1999), white matter
yperintensitiesweremore strongly associatedwith amnesticMCI,
hereas infarctsweremore strongly associatedwithnon-amnestic
CI (Luchsinger et al., 2009).
. Discussion
Previous studies have sought to clarify the role ofAPOE genotype
y contrasting cognitively normal and cognitively impaired partici-
ants, mainly in the older age range. Based on the studies reviewed
bove we conclude that this strategy is unlikely to yield consistent
esults. Because of the interaction ofAPOE *E4with amyloid accu-
ulation in both cognitively pre-symptomatic and symptomatic
roups, a distinction needs to be made between APOE effects in
myloid-negative, amyloid-positive asymptomatic, and amyloid-
ositive symptomatic groups. In young or middle-aged healthy
myloid-negative adults, APOE *E4 carrier status is associated with
ubtle changes in brain functional and structural connectivity,
nd in metabolic functions. *E4 carriers may have an increasedvioral Reviews 37 (2013) 1322–1335
incidence of reduced blood ﬂow in cerebral capillaries. Cholinergic
function affecting cognitionmay be subtly reduced or qualitatively
altered in genetic subgroups, but reduction can most likely only be
shown in experimental tasks of attention orworkingmemory. Hip-
pocampal volumemaybe reducedeven inbabieswith the *E4allele,
but the evidence that *E4 is associated with hippocampal volume
is signiﬁcantly weakened by a recent meta-analysis of GWAS data
from17different cohorts (Stein et al., 2012). Also, recentMRstudies
of a largegroupofmenaged50–59years showed frontal rather than
temporal or hippocampal effects (Fennema-Notestine et al., 2011).
Several studies including our own indicate that the *E4 effect on
ﬁber quality andwhitemattermicrostructure is not age-dependent
and thus predates amyloid accumulation. While emphasizing
that the exact biological correlates of diffusion anisotropy are
unclear (Wheeler-Kingshott and Cercignani, 2009), we interpret
the effects of APOE on DTI-derived white matter microstructure
as myelin-related because of the increased radial diffusivity in *E4
carriers. This is also biologically plausible given the role of the
ApoE protein in lipid transport. However, we ﬁnd it difﬁcult to
distinguish between primary myelination and myelin repair pro-
cesses, since these involve similar biological mechanisms (Fancy
et al., 2011). Furthermore, we cannot exclude the possibility that
axonal and synaptic changes are also present, since myelination
is partly activity-dependent (Fancy et al., 2011). The presence of
*E4 compromises cerebral connectivity as evidenced by altered
white matter microstructural properties and functional integra-
tion of resting state networks, including the defaultmode network.
Changes in mitochondrial function affecting energy metabolism
have also been described in PET studies and in gene expression
studies of cerebral tissue.
The cognitive correlates of these biological phenotypes are
insufﬁciently explored, but white matter microstructural integrity
has been associated with behavioral stability as indexed by trial-
by-trial reaction time variability in both young and adult samples
(Fjell et al., 2011; Tamnes et al., 2012) and age-related reduction
in performance on cognitive tests demanding attention or working
memory functions (Madden et al., 2009). In an older study group
(mean age 72 years), Penke et al. (2012) showed that a processing
speed factor common to a number of cognitive tests was strongly
related to a general white matter ﬁber integrity factor. Similarly,
Salami et al. (2012) found that white matter microstructure medi-
ated age-related reductions in processing speed but not episodic
memory, visuospatial abilities, or verbal ﬂuency.
Together, the ﬁndings reviewed above indicate that *E4 is a
vulnerability factor and not a pathogenic factor at ages where
cerebral diseases or injuries are infrequent. This is not to deny
that pathogenic factors that interact with APOE genotype (amy-
loid  accumulation, cholinergic dysfunction) may not be found in
younger groups, but their frequency or intensity is not sufﬁcient to
result in an interaction of APOE genotype with age, suggesting that
the unique genotypic effects on the various biological, brain and
cognitive phenotypes are relatively invariant with age in healthy
subjects.
These conclusions differ from those of earlier reviews and
meta-analyses (Cherbuin et al., 2007; Wisdom et al., 2011). One
reason may be that many previous studies comprised mainly
older participants who were pre-symptomatic and had unknown
amyloid status. Another reason is that earlier studies may have
had a selective focus guided by the general assumption that since
memory deﬁcit is the cognitive hallmark of AD, and hippocampus
atrophy is the neuroimaging hallmark, these traits should also be
present in *E4 carriers in preclinical groups. We suggest that they
appear at a later stage of AD pathological evolution because of
interaction between *E4 and other pathological factors. In light
of recent ﬁndings that a signiﬁcant proportion of middle-aged
asymptomatic individuals are PiB-positive or have pathological
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SF levels of amyloid  (Morris et al., 2010), a distinction should
e made between asymptomatic (amyloid-positive) and healthy
amyloid-negative) individuals. In the absence of positive evidence,
nly cognitively normal individuals below the age of 40–50 can
e assumed to be amyloid-negative. The traits characterizing *E4
ffects as such in amyloid-negative groups are not disease-speciﬁc
nd are qualitatively different from those found in AD.
The methods for quantifying amyloid  accumulation in vivo
ave only recently become available on a large scale. Pike et al.
2011) compared 58 amyloid-positive cognitively intact persons
ith amyloid-negative controls and found a signiﬁcant interaction
f amyloid burden andAPOE status relative to visuospatial function.
he amyloid-positive group also had poorer memory and higher
ncidence of APOE *E4. The study by Kantarci et al. (2012) further
upports the conclusion that amyloid load and APOE interact in
nﬂuencingmagnitude and proﬁle of pre-clinical cognitive changes
nd risk of further cognitive decline (Villemagne et al., 2011). The
tage at which this decline is sufﬁcient to elicit a clinical classiﬁca-
ion of MCI depends on criteria that vary between studies (Stephan
t al., 2012).
When individuals progress to develop MCI and AD, APOE *E4
nteracts with other pathological factors to drive and shape this
rocess. Most potent among these factors is accumulation of amy-
oid , which biases the pathological course of events toward AD.
t is possible that poorer quality of myelination in *E4 carriers
ncreases vulnerability to amyloid accumulation (Braak and Braak,
997) although the mechanism is unknown. Mahley and Huang
2009) postulate the necessity of pathological factors in addition to
myloid accumulation (“second hit”) in order to trigger AD. There
s evidence that tau accumulation is critical for initiating a further
athological course (Hyman, 2011), and there are indications that
POE *E4 does not affect tau-related mechanisms (Desikan et al.,
n press; Morris et al., 2010). Nevertheless, several APOE-related
echanisms may still inﬂuence the course of pathological devel-
pment.
Allelic variation in cholinergic genes or other factors leading
o reduced receptor efﬁciency may be a contributing factor, as
ay any neurotraumatic event that increases demand for neuronal
epair (Herrup, 2010). Other susceptibility alleles, as yet unknown
ut enriched in individuals with a family history of AD, may also
ffect disease progression. APOE *E4 in association with having a
rst degree relative with AD indicates risk of memory decline from
ge 60 or before (Caselli et al., 2009). Increased cortical PiB binding
as observed in *E4 carriers over 55 with a family history of AD
Xiong et al., 2011).
Since *E4 is associatedwith several cerebrovascular risk factors,
nd especially with reduced cerebral capillary circulation as seen
n CAA, *E4 carriers are more likely to develop a form of MCI,
nd later AD, with signiﬁcant vascular components. *E4 carrier
tatus is associated with a clinical cognitive phenotype with
igniﬁcant episodic memory deﬁcit (amnestic MCI) and higher risk
f conversion to AD (Wolk and Dickerson, 2010). These patients
lso show volume reduction of the hippocampus on MR scans as
ell as widespread, mainly posterior, cortical thinning (Whitwell
t al., 2007). Amyloid accumulation accelerated by APOE *E4 and
ligomer toxicity directly affecting neurons are widely believed
o be causal mechanisms. This is contradicted by Desikan et al. (in
ress), who ﬁnd that entorhinal cortical atrophy occurs only in the
resence of reduced CSF phosphorylated tau. The hippocampal
egion is not a site of early amyloid accumulation as demonstrated
y both pathological (Braak and Braak, 1997; Price et al., 1991) and
ET biomarker data (Aizenstein et al., 2008). The hippocampus is
ighly vulnerable to circulatory failure, as evidenced by hippocam-
al damage and amnesia in anoxic conditions and temporary
irculatory arrest (Horstmann et al., 2010) or chronic hypoperfu-
ion (Cechetti et al., 2012). Thal et al. (2010) have argued for anvioral Reviews 37 (2013) 1322–1335 1331
*E4-related AD subtype, and suggested that clinical AD is not the
end result of a single, sequentially unfolding process. Cholinergic
deﬁcits are more likely to affect the temporal lobe (Haense et al.,
2012) but it has not yet been shown directly that these deﬁcits are
accentuated in *E4 carriers.
The conclusions of this review are consistent with theories of
AD development allowing for heterogenous mechanisms, such as
those proposed by (Herrup, 2010) and implied in the criteria for
deﬁning an AD pathophysiological process as proposed by Sperling
et al. (2011). Our conclusions deviate from a strict version of the
cascade model of Jack et al. (2010) in two ways. Firstly, in relation
to the role of APOE genotype in the AD pathophysiological pro-
cess, we conclude that the cascade model is oversimpliﬁed. While
acknowledging amyloid  as a highly signiﬁcant pathological fac-
tor at initial stages of disease, we ﬁnd that there is a high degree
of diversity of APOE-related pathologicalmechanisms, affecting the
rate andbiomarker proﬁle of clinical development. Secondly, subtle
MR and cognitive markers are detectable early in the development
of the pathophysiological process that render *E4 carriers vulner-
able to MCI and AD, but they are not watered-down versions of
the changes seen in clinical AD, such as hippocampal atrophy and
memory deﬁcit.
5.1. Conclusions
The studies and ﬁndings discussed above enable us to offer an
answer to the ﬁve questions posed initially.
1. How does APOE *E4 increase the risk of early disease presenta-
tion?
The well-documented ability of *E4 to accelerate and possibly
induce amyloid  accumulation is the most likely mechanism.
Subtle pre-symptomatic changes in brain myelination, brain
morphology and cognitive functions may render *E4 carriers
more vulnerable (Bartzokis, 2011).
2. Why do some carriers of *E4 not develop AD?
A “second hit” by another age-associated pathological factor
must be present in addition to amyloid  accumulation. This
factor may be unrelated to APOE genotype, e.g. tauopathy, or
only weakly associated with *E4, such as any process placing
increasing demand on neuronal repair.
3. When does APOE genotype ﬁrst affect the biomarker phenotype
and what are the underlying mechanisms?
There are APOE-dependent effects throughout the lifespan,
with a crucial difference between early and late effects. The
distinction is marked by the time point of signiﬁcant amyloid
 accumulation (about 50–60 years) and not by age in itself.
Myelination, metabolic function, cholinergic receptor activity,
and vascular capillary function (blood ﬂow) are the most rele-
vant mechanisms in the early phase. In PiB-positive individuals,
APOE interactswith amyloid to determine a cognitive and neu-
rodegenerative pattern that is further accentuated in MCI.
4. Which biomarkers are most sensitive to ApoE-related mecha-
nisms?
Accumulation of amyloid  in brain, as measured with an
amyloid-speciﬁc ligand, and CSF is increased in *E4 carriers.
MRI brain imaging studies have consistently shown *E4-related
effects on measures of white matter microstructure and func-
tional connectivity between brain regions. Measures of cortical
and subcortical atrophy have shown more variable results, per-
haps because of differences in sample characteristics. There is no
evidence that any of these markers are speciﬁc to APOE.5. Are there clinical phenotypes speciﬁcally related to APOE geno-
type?
Biomarkers may combine to deﬁne a complex phenotype.
Besidesmemory problems, individuals with amnestic MCI show
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a pattern of hippocampal atrophy and increased risk of develop-
ing AD. This group has a high proportion of *E4 carriers. AD with
associated vascular disease (CAA) is the best candidate for status
as an *E4-speciﬁc AD phenotype.
As the number of long-term longitudinal population studies
ontinues to increase, it is important to cast the netwidely to detect
arly effects of APOE genotype on imaging and cognitive pheno-
ypes. Careful observation of these early markers will be important
or developing treatment strategies targeted toward APOE-related
echanisms (Mahley and Huang, 2009).
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